Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular surface changes after combination therapy of hyaluronate 0.15% and 0.3% in dry eye patients
KCT0004214Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2017
- Countries
- 1
- Modality
- Recombinant Proteins and Enzymes
- Drugs
- sodium hyaluronate
- Conditions
- dry eye syndrome (DED)
01
Overview
Phase 4 trial of sodium hyaluronate in dry eye syndrome (DED), sponsored by Taejoon Pharmaceutical Co., Ltd. Started Oct 2017; status: completed.
02
Who it enrols
Adult patients with dry eye disease receiving combination therapy of 0.15% and 0.3% hyaluronate eye drops; detailed inclusion and exclusion criteria are not specified in the registry entry.
Beyond the preview
Go deeper on KCT0004214.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004214.